Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Gains from Sales and Divestitures: 2017-2022

Historic Gains from Sales and Divestitures for Arcus Biosciences (RCUS) over the last 6 years, with Dec 2022 value amounting to $500,000.

  • Arcus Biosciences' Gains from Sales and Divestitures rose 30.83% to $500,000 in Q4 2022 from the same period last year, while for Dec 2022 it was $500,000, marking a year-over-year increase of 30.83%. This contributed to the annual value of $500,000 for FY2022, which is 30.83% up from last year.
  • Per Arcus Biosciences' latest filing, its Gains from Sales and Divestitures stood at $500,000 for FY2022, which was up 30.83% from $382,183 recorded in FY2021.
  • Over the past 5 years, Arcus Biosciences' Gains from Sales and Divestitures peaked at $500,000 during FY2022, and registered a low of $6,250 during FY2020.
  • Moreover, its 3-year median value for Gains from Sales and Divestitures was $382,183 (2021), whereas its average is $296,144.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first slumped by 98.32% in 2020, then soared by 6,014.93% in 2021.
  • Yearly analysis of 5 years shows Arcus Biosciences' Gains from Sales and Divestitures stood at $14,918 in 2018, then skyrocketed by 2,398.82% to $372,774 in 2019, then crashed by 98.32% to $6,250 in 2020, then skyrocketed by 6,014.93% to $382,183 in 2021, then surged by 30.83% to $500,000 in 2022.